Vilon

Vilon (L-Lys-L-Glu, or lysylglutamate) is a synthetic dipeptide composed of just two amino acids: lysine and glutamate. Despite its remarkably simple structure, it is considered one of the most biologically active peptide bioregulators known, demonstrating that molecular size does not limit biological potency. Vilon is modeled after signaling peptides found in thymus extracts and belongs to the same family of geroprotective bioregulators developed by the Khavinson group in the Soviet Union beginning in the 1970s.

Vilon's primary mechanism of action operates at the epigenetic level. Its short peptide chain can bind directly to double-stranded DNA and histone proteins, modulating chromatin accessibility and reactivating genes that have been silenced through the epigenetic changes associated with aging. This capacity to alter gene expression without modifying the underlying DNA sequence places Vilon among a class of molecules with genuine epigenetic regulatory activity. Research has documented its ability to modulate the expression of more than 36 different genes in cardiac tissue, suggesting systemic regulatory reach from a structurally minimal molecule.

On the immune side, Vilon promotes proliferation of T-lymphocyte subpopulations, particularly CD5 T-cells and cytotoxic CD8 T-cells. CD5 T-cells regulate immune self-tolerance and prevent autoimmune reactions, while CD8 T-cells form the primary antimicrobial and antiviral defense. Vilon also boosts interleukin-2 (IL-2) signaling, a key cytokine for T-cell activation and survival, and stimulates calcium-driven activation cascades in thymocytes and macrophages. The combined effect rebalances immune function rather than bluntly stimulating it.

Beyond immune modulation, Vilon has demonstrated vascular protective effects in animal research. In kidney tissue, it reduces transforming growth factor-beta-1 (TGF-beta-1) concentration and decreases microvascular permeability, both of which are markers of age-related vascular dysfunction. Long-term animal studies have shown that Vilon treatment can prolong lifespan, slow spontaneous tumor development, and support metabolic and vascular homeostasis. As with other peptide bioregulators, human clinical data are limited and the peptide is not approved for use outside Russia and Eastern Europe.